Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Starlix

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Company will seek a diabetes prevention claim for its type 2 diabetes drug Starlix with data generated from an 8,000 patient outcomes study, the firm tells analysts. The trial's primary endpoints will be prevention of impaired glucose tolerance progression to type 2 diabetes and improved cardiovascular outcomes. Novartis will begin enrollment by late summer, and results could be available by 2004-2005. The company is getting ready to launch the irritable bowel syndrome treatment Zelmac mid-year and the asthma therapy Xolair, which is being developed with Genentech and Tanox, by the end of the yea
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS001406

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel